<DOC>
	<DOCNO>NCT00896298</DOCNO>
	<brief_summary>Lipodystrophies represent therapeutic challenge regard insulin resistance , hypertriglyceridemia fatty liver often couple significant adipose tissue loss . The purpose study examine safety efficacy Leptin subject lipodystrophy .</brief_summary>
	<brief_title>Trial Leptin Replacement Therapy Patients With Lipodystrophy</brief_title>
	<detailed_description>The mechanism leptin improve glucose lipid control clear . We examine possible mechanism leptin action study effect leptin administration food intake , insulin resistance , insulin secretory response , hepatic intramuscular triglyceride store large sample patient lipodystrophy . Hypothesis : Leptin replacement patient generalize partial lipodystrophy hypoleptinemia safe efficacious improve metabolic abnormality associate insulin resistance .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Lipodystrophy , Congenital Generalized</mesh_term>
	<criteria>age &gt; 6 year Partial generalize lipodystrophy Serum leptin level less 7th percentile normal value report 3rd National Health Nutrition Examination survey ( le 7.0 ng/mL female less 3/0 ng/mL male ) Presence least one follow metabolic abnormality : 1 . Type 2 Diabetes Mellitus 2 . Fasting serum insulin &gt; 20 uU/mL 3 . Fasting serum triglyceride &gt; 300 mg/dL 4 . Previous participation leptin trial ( Amgen 991265 , GCRC 660 ) Part B Study . Known liver disease due cause nonalcoholic steatohepatitis . Hematocrit le 30 % . Current alcohol substance abuse . Use anorexigenic drug , anabolic steroid , GH thiazolidinediones Active tuberculosis Psychiatric disorder impede competence compliance Malignancies HIV infection Subjects know hypersensitivity E. Coli derive proteins Other condition , opinion clinical investigator would impede completion study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Lipodystrophy</keyword>
	<keyword>Insulin secretory response</keyword>
</DOC>